Outlook Therapeutics, Inc. — Director's Dealing 2016

May 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncobiologics, Inc. (ONS)
CIK: 0001649989
Period of Report: 2016-05-18

Reporting Person: Brady Todd C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-05-18	Common Stock	C	66333	$0.00	Acquired	124303	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-18	Series A Preferred Stock	$0.00	C	398	Disposed		Common Stock ()	Direct

Footnotes

F1: The reporting person's 398 shares of Series A Preferred Stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering ("IPO") based on dividing the aggregate liquidation preference of $398,000 by the IPO price per share included in the units sold in the IPO.

F2: N/A

F3: There is no expiration date.